Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns Buy Rating from Analysts at Canaccord Genuity Group

Key Points

• Canaccord initiated coverage on Lineage Cell Therapeutics with a Buy rating and a $9 price target, implying roughly a 480.65% upside from the prior close.
• Consensus among analysts is positive—four analysts rate LCTX as Buy with an average target of $6.25—while shares trade around $1.55 with a market cap of about $386.1 million and a 12‑month range of $0.43–$2.09.
• Lineage is a clinical‑stage biotech focused on allogeneic cell therapies (lead candidate OpRegen for geographic atrophy); it recently topped revenue estimates ($6.61M vs. $1.96M) but remains unprofitable with a negative net margin and forecasted negative EPS for the year.

Equities researchers at Canaccord Genuity Group started coverage on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report) in a note issued to investors on Tuesday, MarketBeat.com reports. The brokerage set a "buy" rating and a $9.00 price target on the stock. Canaccord Genuity Group's price target indicates a potential upside of 480.65% from the company's previous close.

LCTX has been the subject of a number of other research reports. HC Wainwright reissued a "buy" rating and issued a $9.00 price objective on shares of Lineage Cell Therapeutics in a research report on Tuesday, March 24th. B. Riley Financial raised their price objective on Lineage Cell Therapeutics from $3.00 to $4.00 and gave the stock a "buy" rating in a research report on Wednesday, March 25th. Finally, D. Boral Capital raised their price objective on Lineage Cell Therapeutics from $2.00 to $3.00 and gave the stock a "buy" rating in a research report on Friday, March 6th. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $6.25.

Lineage Cell Therapeutics Stock Performance

Shares of NYSEAMERICAN LCTX opened at $1.55 on Tuesday. The stock has a market capitalization of $386.09 million, a PE ratio of -5.54 and a beta of 1.79. Lineage Cell Therapeutics has a 12-month low of $0.43 and a 12-month high of $2.09. The stock's fifty day simple moving average is $1.65 and its two-hundred day simple moving average is $1.69.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report) last posted its quarterly earnings data on Thursday, March 5th. The company reported $0.00 earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.07. The firm had revenue of $6.61 million during the quarter, compared to analysts' expectations of $1.96 million. Lineage Cell Therapeutics had a negative return on equity of 76.13% and a negative net margin of 436.47%. On average, equities analysts predict that Lineage Cell Therapeutics will post -0.08 earnings per share for the current fiscal year.

Institutional Trading of Lineage Cell Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LCTX. SG Americas Securities LLC acquired a new stake in Lineage Cell Therapeutics during the 4th quarter worth about $25,000. Citizens Financial Group Inc. RI acquired a new stake in Lineage Cell Therapeutics during the 3rd quarter worth about $25,000. Jump Financial LLC acquired a new stake in Lineage Cell Therapeutics during the 2nd quarter worth about $28,000. DLD Asset Management LP acquired a new stake in Lineage Cell Therapeutics during the 4th quarter worth about $33,000. Finally, Define Financial LLC acquired a new stake in Lineage Cell Therapeutics during the 4th quarter worth about $33,000. Institutional investors and hedge funds own 62.47% of the company's stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.